Genitourinary rhabdomyosarcoma: which treatment, how much, and when?

[1]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Winkler,et al.  Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Thomas Völker,et al.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Walterhouse,et al.  Optimal Management Strategies for Rhabdomyosarcoma in Children , 2007, Paediatric drugs.

[6]  James R. Anderson,et al.  Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. , 2006, The Journal of urology.

[7]  H. Snyder,et al.  Bladder/prostate rhabdomyosarcoma: miles to go before we sleep. , 2006, The Journal of urology.

[8]  F. Ferrer,et al.  Bladder/prostate rhabdomyosarcoma: past, present and future. , 2006, The Journal of urology.

[9]  D. Rodeberg,et al.  Significance of Persistent Mature Rhabdomyoblasts in Bladder/Prostate Rhabdomyosarcoma: Results From IRS IV , 2006, Journal of pediatric hematology/oncology.

[10]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Cox,et al.  Outcome after surgical resection of recurrent rhabdomyosarcoma. , 2006, Journal of pediatric surgery.

[12]  H. Bruschini,et al.  Does the less aggressive multimodal approach of treating bladder-prostate rhabdomyosarcoma preserve bladder function? , 2005, The Journal of urology.

[13]  M. Hudson,et al.  Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Fraumeni,et al.  The risk of developing second cancers among survivors of childhood soft tissue sarcoma , 2005, Cancer.

[15]  James R. Anderson,et al.  Rhabdomyosarcoma: many similarities, a few philosophical differences. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. B. Marsden,et al.  Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Stevens.  Treatment for childhood rhabdomyosarcoma: the cost of cure. , 2005, The Lancet. Oncology.

[18]  F. Ullrich,et al.  Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study iv. , 2004, The Journal of urology.

[19]  James R. Anderson,et al.  Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group , 2004, Pediatric blood & cancer.

[20]  A. Ferrari,et al.  Primary transcrotal excision for paratesticular rhabdomyosarcoma , 2003, Cancer.

[21]  M. Stevens,et al.  Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Ferrari,et al.  Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Meza,et al.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. , 2001, International journal of radiation oncology, biology, physics.

[24]  S. Donaldson,et al.  Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? , 2001, Seminars in pediatric surgery.

[25]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  James R. Anderson,et al.  What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? , 2001, Cancer.

[27]  James R. Anderson,et al.  Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.

[28]  T. Triche,et al.  Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for the outcome. , 2000, Journal of pediatric hematology/oncology.

[29]  G. Henze,et al.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Pappo,et al.  Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Haie-meder,et al.  Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Qualman,et al.  Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-year review from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of pediatric surgery.

[33]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Pritchard,et al.  Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. , 1994, British Journal of Cancer.

[35]  R. Heyn,et al.  Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the intergroup rhabdomyosarcoma study committee , 1993, Cancer.

[36]  P. Voûte,et al.  Paraaortic lymphadenectomy is not necessary in the treatment of localized paratesticular rhabdomyosarcoma , 1984, Cancer.